BioVersys Net Loss Widens in H1; Revenue Returns

01:24 AM EDT, 09/09/2026 (MT Newswires) -- BioVersys (BIOV.SW) said Wednesday that its attributable net loss widened in the first half, while revenue returned year over year. Net loss attributable to owners of the parent for the six months ended June 30 was 15.6 million francs, compared with 11 million francs earlier. Loss per share moved to 2.66 francs from 2.05 francs. The clinical-stage biopharmaceutical company's revenue was 800,000 francs, compared with no revenue a year ago. For full-year 2026, the company revised its guidance and now expects its operating loss to be in the range of 32 million francs to 34 million francs, compared with the prior expectations of a total operating loss of between 40 million francs and 45 million francs.